Cite
HARVARD Citation
Harada, D. et al. (2019). A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. Asia-Pacific journal of clinical oncology. 15 (4), pp. 250-256. [Online].